Carmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibitor that specifically inhibits the phosphorylation of MET receptors and downstream signaling proteins mediated by MET, thereby inhibiting the proliferation and migration of c-MET-dependent tumor cells and inducing apoptosis. Clinically, it is used to treat adult patients with metastatic non-small cell lung cancer. This drug has the ability to cross the blood-brain barrier and also shows some inhibitory efficacy against brain tumor lesions.
Carmatinib (Tabrecta) Price
Currently, there are several versions of carmatinib (Tabrecta) on the market, and the prices of different versions vary:
Laos Lucius Version
This generic version of carmatinib, manufactured by Lao Lucius Pharmaceuticals, is available in a specification of 200mg × 60 tablets/box. Based on current market information, its price is approximately $2650 to $3100 per box.
Novartis's Swiss version of Carmatinib. The original Novartis drug is available in two strengths: 200mg*60 tablets and 150mg*60 tablets, priced between approximately US$4,282 and US$62,100.
The above prices are for reference only. The actual price of Carmatinib will vary depending on factors such as exchange rate fluctuations, sales region, drug version, and purchase channel. Given the uncertainty of prices, it is strongly recommended to verify the latest price before purchasing. Please also remember to purchase medication through legitimate channels.
How to Purchase Carmatinib (Tabrecta)
The main channels for purchasing Carmatinib (Tabrecta) are as follows:
Hospital Pharmacies: In regions where this drug has been approved for marketing, patients can purchase it directly from hospital pharmacies with a doctor's prescription.
Online Pharmacies: Legitimate online pharmacies may offer this drug. It is necessary to verify that the website has the legal qualifications to sell pharmaceuticals and carefully verify the source of the drug.
Pharmacy Retail Chains: Some large pharmacy retail chains may sell it. Consult your local pharmacy for specific details.
Medical Institutions:Patients can consult reputable medical institutions in China to inquire about their assistance in purchasing the required version of carmatinib and to obtain the latest price information.
Side Effects of Carmatinib (Tabrecta)
Common side effects of carmatinib in clinical use include:
Edema
A frequent side effect, often manifesting as swelling of the hands and feet, facial edema, etc.
Nausea
A typical gastrointestinal reaction, often accompanied by loss of appetite, which may affect nutrient intake and quality of life.
Vomiting
If severe and not treated promptly, it may lead to dehydration and other complications.
Fatigue
Patients may experience persistent fatigue and weakness, which can affect their daily activities.
Patients must strictly follow their doctor's instructions during medication. If any side effects occur, they should inform their doctor immediately so that the doctor can take appropriate measures.
